Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alonso-Abreu Inmaculada, Ramos Laura, Hernandez-Camba Alejandro, Yagüe-Caballero Carmen, Vicente Lidón Raquel, Taxonera Carlos, García-Brenes Miguel A, Gisbert Javier P, Chaparro Maria, Madero Velázquez Lucia, Carrillo-Palau Marta, Arranz Laura, Castro Senosiain Beatriz, García de la Filia Molina Irene, Rojas-Feria María, López Romero-Salazar Francisco, Bastón-Rey Iria, Sánchez-Azofra María, Riestra Sabino, Pérez-Galindo Pablo, Ortega Moya Silvia Patricia, Brunet-Mas Eduard, Segura Patricia Sanz, Caballero Mateos Antonio M, Calafat Margalida, Botella Mateu Belén, Manceñido Marcos Noemí, Rodríguez-Lago Iago, Ferrer Cristina Suarez, Gutiérrez Ana
Аннотация
OBJECTIVES: This study aimed to assess whether the coexistence of CeD and IBD is associated with a differential IBD disease course.
DESIGN: Multicenter case-control study.
METHODS: This study included patients with both CeD and IBD, and controls with IBD alone in a 1:2 ratio, matched by sex, IBD type, and year of diagnosis. CeD was diagnosed based on a Marsh score >1. Data on IBD phenotype and treatment, mortality and neoplasm development were collected from medical records.
RESULTS: The study included 66 celiac-IBD patients (30 ulcerative colitis, 6 indeterminate colitis, 30 Crohn's disease; mean age 30 ± 14 years) and 132 non-celiac-IBD patients (68 ulcerative colitis, 4 indeterminate colitis, 60 Crohn's disease; mean age 32 ± 14 years). Among patients with CeD, Marsh type 3 was the most frequently observed lesion. No significant differences were observed between celiac and non-celiac-IBD patients in terms of IBD extension, extraintestinal manifestations, or coexisting autoimmune diseases. Similarly, no differences were found in outcomes including perianal disease, use of mesalamine, immunomodulators, biologics, need for surgery, or development of neoplasms. No deaths occurred in either group.
CONCLUSION: In this large multicenter cohort, the concurrent diagnosis of CeD and patients with IBD was not associated with a different IBD phenotype or worse outcomes compared to non-celiac-IBD patients. The coexistence of CeD does not appear to alter the natural history of IBD.